Health · Medical Research · 2 hrs ago
Porto Alegre hospital offers Brazil’s first Anvisa-approved Alzheimer’s blood test
Hospital Moinhos de Vento in Porto Alegre is offering Brazil’s first blood test for Alzheimer’s approved by Anvisa, the country’s health regulator.
The test looks for p-tau217, a protein linked to brain changes associated with Alzheimer’s.
A positive result can point to disease-related processes, but doctors use the test alongside other assessments such as a person’s mental state and medical history.
It offers a less invasive option than tests involving a spinal-fluid sample or PET imaging.
For now, the test is private, requires a prescription and costs R$3,200.
The hospital expects to work with partners to make it available through health plans and Brazil’s public health system later this year.
Hospital Moinhos de Vento in Porto Alegre is the first institution in Brazil to offer an Anvisa-approved blood test to help investigate and diagnose Alzheimer’s.
The test detects p-tau217, a protein associated with brain changes related to Alzheimer’s.
It is available privately with a medical prescription and costs R$ 3,200.
The hospital says it hopes to make the test available through health plans and Brazil’s public health system later this year through partnerships.
The test is intended to support doctors’ assessments, not replace other parts of diagnosis.
- Who
- Hospital Moinhos de Vento is offering the test. People can take it with a medical prescription.
- What
- It is an Anvisa-approved blood test that helps investigate and diagnose Alzheimer’s by detecting the p-tau217 protein.
- When
- It was reported as available on October 15, 2026.
- Where
- Hospital Moinhos de Vento in Porto Alegre, Brazil.
- Why
- The test can help doctors identify biological signs associated with Alzheimer’s and offers a less invasive alternative to some existing methods.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Institution
- Hospital Moinhos de Vento
- Location
- Porto Alegre, Brazil
- Test biomarker
- p-tau217
- Private cost
- R$ 3,200
- Approval
- Registered with Brazil’s National Health Surveillance Agency (Anvisa)
3 sources
Exame de sangue capaz de diagnosticar o Alzheimer chega ao Brasil
Primeiro exame de sangue para Alzheimer com registro na Anvisa chega ao Brasil: veja quem pode fazer, quanto custa e o que o resultado revela
Hospital de Porto Alegre é o primeiro do Brasil a oferecer exame de sangue para investigar Alzheimer aprovado pela Anvisa
What people are saying
In this scenario, the test represents a transformative and cost-effective alternative that can identify the biological signs of the disease in a less invasive way through blood analysis